Senator Bernie Sanders used his first hearing as chair of the Senate Health, Education, Labor, and Pensions Committee to publicly shame Moderna's CEO over a planned COVID-19 vaccine price increase. According to reporting by KHN, the Vermont independent's new gavel gave him a microphone, not a policy lever, when it comes to drug prices.
Sanders opened by calling prescription drug costs "outrageous" while executives become billionaires. CEO Stéphane Bancel sat on the witness stand and refused to commit to a price rollback, even after Sanders asked for one. The exchange laid bare both the populist appeal of attacking pharma and the limits of a committee that does not actually set drug prices.
Key facts
- HELP has jurisdiction over public health but not over Medicare, Medicaid, or drug pricing, which sit with the Senate Finance Committee.
- Moderna received billions in federal research and purchase funding before bringing any product to market.
- Bancel held about $3 billion in Moderna stock as of early March.
- The drugmaker says it will move its latest COVID vaccine from roughly $26 a shot to between $110 and $130.
- Republicans on the panel split: Braun and Marshall called the hike "outrageous" and "absurd," while Romney defended Bancel's right to a profit.
What just happened, and what it does not change
Sanders turned the session into a morality play. He sketched a future in which Washington would underwrite drug research and then dictate the resulting prices, pressing Bancel on what he saw as wrong about a model that prices lifesaving medicine out of reach. That is an ideal, not a bill.
Moderna's pricing power rests on patents, FDA approvals, and Medicare reimbursement rules, none of which HELP directly rewrites. The hearing produced one headline, no votes, and no concession from Bancel. The real pressure on drugmakers tends to be indirect: a White House push tied to other priorities, as seen when insulin prices fell after political heat earlier this year.
Our analysis
Sanders' position is awkward. He has spent decades railing against pharma, and now he is running the panel that meets the industry but cannot bind it. The hearing worked as advertising for a future Sanders drug-pricing bill that may or may not arrive.
There is also a credibility cost. By inviting Bancel to defend a $110 vaccine, Sanders set up a fight he could not win on policy terms. Bancel only had to wait him out. Bully-pulpit moments turn into lower prices when the executive branch or other committees are ready to use real use, as happened with insulin.
For the industry, the takeaway is that even Republican senators are now publicly labeling big price hikes as absurd. The political space for large, visible increases on vaccines developed with public funding is narrowing quickly. Watch whether that shift reaches beyond the dais.
A practical scenario
Say you are uninsured or underinsured and you need a COVID booster this fall. Under the new pricing, the cost to you or your insurer could more than quadruple. For most Americans with commercial coverage, that cost is hidden inside premiums. For those on Medicare or paying cash, it is not. Check your insurer's preventive care rules, since vaccine coverage is set separately from drug pricing.
What to watch next
Keep an eye on the Senate Finance Committee for any actual drug-pricing bill. Watch how the Biden administration structures its fall vaccine purchase. And watch whether the viral moment forces Moderna to back off the $110 figure before the next booster season.
Key takeaways
- HELP has a microphone on drug prices, not a vote.
- The Moderna showdown was political theater with a real cost: the price of the next booster.
- Insulin showed that pressure from other angles can move prices; this hearing did not.
Frequently asked questions
What can the HELP Committee actually do about drug prices?
HELP oversees public health agencies and programs but not Medicare, Medicaid, or drug pricing, which are handled by the Senate Finance Committee.
Why was Moderna's vaccine so expensive to develop?
Moderna received billions in federal research, purchase, and advisory support during the pandemic, according to KHN's reporting, before bringing its first product to market.
Did Bancel commit to lowering the price?
No. According to KHN, he did not promise a price rollback at the hearing.
How did the insulin price cuts happen, and could the same approach work for vaccines?
Insulin prices fell after direct political pressure on manufacturers combined with provisions in the Inflation Reduction Act. Vaccines sit under a different reimbursement system, so the same playbook is harder to apply.